Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM326 in moderate-to-very severe COPD
CTR20253947Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in chronic obstructive pulmonary disease (COPD), sponsored by Keymed Biosciences. Started Dec 2025; status: active.
02
Drugs
CM326
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20253947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253947.